A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback